Article
Immunology
Motoko Yasutomi, Allison F. Christiaansen, Naoko Imai, Natalia Martin-Orozco, Christian V. Forst, Gang Chen, Hideki Ueno
Summary: Research has shown that CD226 plays an important role in the early differentiation of human Tfh cells, while CD155 promotes the proliferation of naive CD4(+) T cells and Tfh precursors and regulates the expression of multiple Tfh molecules. Blocking CD226 inhibits the proliferation and expression of Tfh markers. However, attenuating CD226 signals increases the expression of certain molecules in CD155-stimulated GC-Tfh cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Tomohei Matsuo, Akiko Iguchi-Manaka, Akira Shibuya, Kazuko Shibuya
Summary: CD155 is a ligand that can activate or inhibit immune receptors, namely DNAM-1 and TIGIT, which play roles in regulating tumor immune responses in natural killer cells and T cells. Recent research suggests that a mutation in CD155, resulting in decreased affinity for DNAM-1, is associated with worse overall survival in small cell lung cancer patients. However, our findings show that this mutation actually increases the binding affinity for TIGIT and leads to a stronger signal, suppressing immune responses in the tumor microenvironment.
Article
Immunology
Annerose E. Ziegler, Pia Fittje, Luisa M. Mueller, Annika E. Ahrenstorf, Kerri Hagemann, Sven H. Hagen, Leonard U. Hess, Annika Niehrs, Tobias Poch, Gevitha Ravichandran, Sebastian M. Loebl, Benedetta Padoan, Sebastien Brias, Jana Hennesen, Myrtille Richard, Laura Richert, Sven Peine, Karl J. Oldhafer, Lutz Fischer, Christoph Schramm, Gloria Martrus, Madeleine J. Bunders, Marcus Altfeld, Sebastian Lunemann
Summary: The interaction between NK cells and their surrounding environment is regulated by activating and inhibitory receptors. The inhibitory receptor TIGIT reduces NK cell cytotoxicity and is involved in NK cell exhaustion, but it is also associated with liver regeneration. The role of human intrahepatic CD56(bright) NK cells in tissue homeostasis regulation is not fully understood.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Kazuki Sato, Yumi Yamashita-Kanemaru, Fumie Abe, Rikito Murata, Yuho Nakamura-Shinya, Kazumasa Kanemaru, Masafumi Muratani, Andre Veillette, Motohito Goto, Mamoru Ito, Akira Shibuya, Kazuko Shibuya
Summary: DNAM-1 regulates Treg cell function via TIGIT signaling, and can potentially serve as a molecular target for enhancing Treg function in inflammatory diseases.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Duygu Ozmadenci, Jayanth S. Shankara Narayanan, Jacob Andrew, Marjaana Ojalill, Allison M. Barrie, Shulin Jiang, Samhita Iyer, Xiao Lei Chen, Michael Rose, Valeria Estrada, Alfredo Molinolo, Thomas Bertotto, Zbigniew Mikulski, Michael C. McHale, Rebekah R. White, Denise C. Connolly, Jonathan A. Pachter, Vijay K. Kuchroo, Dwayne G. Stupack, David D. Schlaepfer
Summary: High-grade serous ovarian cancer (HGSOC) is a lethal malignancy with immunosuppressive tumor microenvironment. This study reveals the association between elevated active focal adhesion kinase (FAK) and TIGIT checkpoint ligands in HGSOC tumors. Inhibition of FAK activity reduces tumor burden and increases tumor infiltrating lymphocytes (TILs), while combination treatment with FAK inhibitor and TIGIT antibody prolongs host survival and promotes lymphoid structure formation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Medicine, Research & Experimental
Lu Liu, Aihong Wang, Xiaoli Liu, Sai Han, Yu Sun, Junhua Zhang, Lingyu Guo, Youzhong Zhang
Summary: Objective TIGIT/CD155 has been identified as a potential therapeutic target in cervical cancer. This study demonstrated that high expression of TIGIT promotes the exhaustion of CD8(+) T lymphocytes and inhibits cytokine production. Blocking TIGIT/CD155 restores the function of CD8(+) T cells and inhibits tumor growth. Therefore, TIGIT/CD155 is considered a promising therapeutic target for cervical cancer.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Toshihide Ueno, Joji Nagasaki, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yasuhiro Nakamura, Tomonori Kawasaki, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Yuzuru Ikehara, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Hiroyuki Matsue, Yosuke Togashi
Summary: Cancer patients benefit from treatment with immune checkpoint inhibitors, especially those with an inflamed tumor microenvironment or high tumor mutation burden. However, some patients develop resistance to ICIs. The TIGIT/CD155 axis has been identified as mediating resistance to ICIs in patients with melanoma with an inflamed TME, suggesting potential for developing TIGIT blockade therapies in this population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Yu-Xi Lin, Mien-Chie Hung, Jye-Lin Hsu, Jung-Mao Hsu
Summary: This study demonstrates that N-glycosylations of TIGIT are critical for its interaction with PVR, especially the N101 residue. These findings suggest that N-glycosylation sites on TIGIT, particularly residue N101, may be potential targets for PVR/TIGIT immune checkpoint blockade.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Oncology
Fangming Wang, Shuai Liu, Fei Liu, Tianli Xu, Jianlin Ma, Jing Liang, Jing Wang, Donghua Liu, Feiya Yang, Jianxing Li, Nianzeng Xing
Summary: The TIGIT monoclonal antibody vibostolimab enhances the antitumor effect of expanded NK cells against CRPC by enhancing cytotoxicity and cytokine production. This finding supports the translational application of TIGIT mAb and NK cell combination strategies for CRPC treatment.
Article
Oncology
Xian Shen, Wenyan Fu, Yongpeng Wei, Junle Zhu, Yue Yu, Changhai Lei, Jian Zhao, Shi Hu
Summary: TIGIT-Fc protein promotes tumor immunity by enhancing effector functions of CD8(+) T and NK cells, inducing Th1 development in CD4(+) T cells, and providing potent antibody-dependent cell-mediated cytotoxicity effects, suggesting it as a promising anticancer therapeutic strategy either alone or in combination with other checkpoint receptor blockers.
CANCER IMMUNOLOGY RESEARCH
(2021)
Review
Oncology
Lu Liu, Xuewu You, Sai Han, Yu Sun, Junhua Zhang, Youzhong Zhang
Summary: CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a novel type of immune checkpoint that inhibits the function of T and NK cells by transmitting immune signals through the inhibitory receptor TIGIT. This mechanism holds promise for further improving the application of immune checkpoint inhibitors in tumor therapy.
Article
Oncology
Liang Mao, Yao Xiao, Qi-Chao Yang, Shao-Chen Yang, Lei-Lei Yang, Zhi-Jun Sun
Summary: This study found that CD155 and PD-L1 are highly co-expressed on MDSCs in HNSCC patients, and the combined blockade of TIGIT/CD155 and PD-1/PD-L1 signaling significantly inhibited tumor growth in mouse models, enhanced the percentage of effector T cells, and induced immune memory effects.
Article
Biochemistry & Molecular Biology
Laszlo Szereday, David U. Nagy, Beata Csiszar, Dora Kevey, Timoteus Feik, Matyas Meggyes
Summary: This study found decreased CD226 expression and increased CD112 and CD155 expression in almost all T cell, NK cell, and monocyte subpopulations in women with early-onset preeclampsia. Additionally, reduced TIGIT and granzyme B expression were observed in preeclamptic CD8+ T cells. These results suggest that inhibitory signals via the TIGIT/CD112 and/or TIGIT/CD155 pathways may contribute to immune response inhibition in early-onset preeclampsia.
Article
Multidisciplinary Sciences
Daisuke Murakami, Kenji Matsuda, Hiromitsu Iwamoto, Yasuyuki Mitani, Yuki Mizumoto, Yuki Nakamura, Ibu Matsuzaki, Ryuta Iwamoto, Yuichi Takahashi, Fumiyoshi Kojima, Shin-Ichi Murata, Hiroki Yamaue
Summary: The interaction between CD155 and TIGIT may play an important role in the immunological mechanism of colorectal cancer. High expression of CD155 and TIGIT is associated with worse prognosis. Evaluation of the combined expression of CD155 and TIGIT may effectively predict the postoperative prognosis of colorectal cancer.
Article
Biochemistry & Molecular Biology
Matyas Meggyes, David U. Nagy, Timoteus Feik, Akos Boros, Beata Polgar, Laszlo Szereday
Summary: The study highlights the significance of immune checkpoint molecules in immune regulation during pregnancy. CD226 appears to be a crucial regulator, particularly in CD4(+) T and NKT cells, contributing to maternal immune tolerance in the late phase of pregnancy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Qian Cheng, Debao Qu, Zheng Lu, Longzhen Zhang
Article
Pharmacology & Pharmacy
Zhenkun Zong, Lei Hua, Zhen Wang, Haoyue Xu, Chengkun Ye, Bomin Pan, Zongren Zhao, Longzhen Zhang, Jun Lu, Liu Hong Mei, Yu Rutong
Article
Cell Biology
Nianli Liu, Zhiyuan Wu, Aoxing Chen, Dafei Chai, Liantao Li, Longzhen Zhang, Junnian Zheng
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2019)
Correction
Immunology
Qing Zhang, Haixu Zhang, Jiage Ding, Hongyan Liu, Huizhong Li, Hailong Li, Mengmeng Lu, Yangna Miao, Liantao Li, Junnian Zheng
JOURNAL OF IMMUNOLOGY RESEARCH
(2019)
Article
Cell Biology
Nianli Liu, Zhiyuan Wu, Aoxing Chen, Yuqi Wang, Dafei Cai, Junian Zheng, Yong Liu, Longzhen Zhang
CELL DEATH & DISEASE
(2019)
Article
Multidisciplinary Sciences
Hao Cui, Hongjian Shan, Michael Zhe Miao, Zhiguo Jiang, Yuanyuan Meng, Ran Chen, Longzhen Zhang, Yong Liu
SCIENTIFIC REPORTS
(2020)
Article
Biotechnology & Applied Microbiology
Nianli Liu, Jiayin Ji, Hui Qiu, Zhiying Shao, Xin Wen, Aoxing Chen, Senbang Yao, Xingying Zhang, Hong Yao, Longzhen Zhang
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
(2020)
Article
Medicine, General & Internal
Quanquan Guo, Zhiying Shao, Dan Xu, Lili Fan, Huiru Xiong, Xin Ding, Chuanwen You, Longzhen Zhang
Article
Genetics & Heredity
Qiuwen Sun, Xia Li, Muchen Xu, Li Zhang, Haiwei Zuo, Yong Xin, Longzhen Zhang, Ping Gong
FRONTIERS IN GENETICS
(2020)
Article
Genetics & Heredity
Xin Wen, Zhiying Shao, Shuyi Chen, Wei Wang, Yan Wang, Jinghua Jiang, Qinggong Ma, Longzhen Zhang
Summary: By analyzing RBPs in PAAD, we constructed an RBP-associated prognostic risk model, including 453 differentially expressed RBPs and 28 prognostic-associated RBPs. This model can predict the prognosis of PAAD patients and serve as an independent prognostic indicator.
FRONTIERS IN GENETICS
(2021)
Correction
Nanoscience & Nanotechnology
Yuanzeng Min, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, Laura E. Herring, Longzhen Zhang, Tian Zhang, Joseph M. DeSimone, Joel E. Tepper, Benjamin G. Vincent, Jonathan S. Serody, Andrew Z. Wang
NATURE NANOTECHNOLOGY
(2021)
Article
Health Care Sciences & Services
Zheng Chen, Shu Jiang, Xuechun Li, Jingyao Zhang, Liu Liu, Juan Li, Peiyu Cao, Yong Xin, Longzhen Zhang
Summary: The meta-analysis results showed that combination therapy of anti-angiogenic drugs with erlotinib significantly improved progression-free survival (PFS) in patients with advanced non-small cell lung cancer. Particularly, patients with epidermal growth factor receptor (EGFR) mutations, adenocarcinoma, and Asian populations benefited the most from the treatment.
ANNALS OF PALLIATIVE MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Yang Zhao, Hongchao Zhao, Danhuan Zhang, Qiuying Quan, Yan Ge, Liantao Li, Lingchuan Guo
Summary: In this study, we identified the high expression of YTHDF3 in oxaliplatin-resistant CRC tissues and cells. YTHDF3 was found to recognize and facilitate the translation of significantly m6A-methylated RNAs associated with tumor resistance through its coordination with eIF2AK2.
ACS CHEMICAL BIOLOGY
(2022)
Article
Oncology
Yang Wu, Longzhen Zhang, Tianyou Tang, Liantao Li, Liang Li, Hongmin Yu
Summary: The study found that excluding cervical lymph node radiotherapy after surgery does not have a significant impact on recurrence, survival, and radiation complications in patients with locally advanced supraglottic and glottic laryngeal carcinoma.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Article
Medicine, Research & Experimental
Xingying Zhang, Xin Wen, Ning Feng, Aoxin Chen, Senbang Yao, Xin Ding, Longzhen Zhang
MEDICAL SCIENCE MONITOR
(2020)